RT info:eu-repo/semantics/article
T1 Hydroxychloroquine and Potential Drug Interactions in Older Adults
A1 Velasco-González, Verónica
A1 Fernández-Araque, Ana
A1 Sainz-Gil, María
A1 Jimeno, Natalia
A1 Martín, Luis H
A1 Verde, Zoraida
AB The letter explains that hydroxychloroquine, proposed for COVID‑19 treatment in older adults, has a narrow therapeutic window, slow elimination, and variable pharmacokinetics, which makes drug–drug interactions (DDIs) particularly relevant in this population. The authors describe an analysis of chronic medication in 377 older adults from Northern Spain, in which they identify 47 drugs and highlight 12 frequently used agents (amiodarone, rifampicin, phenobarbital, phenytoin, carbamazepine, digoxin, citalopram, dabigatran, hydroxyzine, nortriptyline, salmeterol and apixaban) as having clinically important potential interactions with hydroxychloroquine that may contraindicate coadministration or demand close monitoring. These interactions are mainly related to effects on CYP2D6 metabolism, P‑glycoprotein transport, and additive QT‑interval prolongation, leading the authors to recommend that clinicians carefully review polypharmacy and monitor for DDIs when prescribing hydroxychloroquine to elderly COVID‑19 patients
PB ELSEVIER
YR 2020
FD 2020-10-01
LK https://uvadoc.uva.es/handle/10324/81728
UL https://uvadoc.uva.es/handle/10324/81728
LA eng
NO Arch Bronconeumol (Engl Ed) . 2020 Oct;56(10):679-681.
DS UVaDOC
RD 17-ene-2026